Preventing Cardiotoxicity Associated With Breast Cancer Therapy
Abstract
News & Analysis Clinical Trials Update Preventing Cardiotoxicity Associated sion severity than did the comparator group. With Breast Cancer Therapy Clinically meaningful improvements were An angiotensin-converting enzyme (ACE) seen in the esketamine group 24 hours af- inhibitor and β-blocker prevented cardio- ter a single dose. In the esketamine group, toxicity associated with combination 7% discontinued the study drug due to ad- chemotherapy in women with ERBB2 verse events compared...